Estimating the proportion of treatment effect explained by a surrogate marker.

In this paper, we measure the extent to which a biological marker is a surrogate endpoint for a clinical event by the proportional reduction in the regression coefficient for the treatment indicator due to the inclusion of the marker in the Cox regression model. We estimate this proportion by applying the partial likelihood function to two Cox models postulated on the same failure time variable. We show that the resultant estimator is asymptotically normal with a simple variance estimator. One can construct confidence intervals for the proportion by using the direct normal approximation to the point estimator or by using Fieller's theorem. Extensive simulation studies demonstrate that the proposed methods are appropriate for practical use. We provide applications to HIV/AIDS clinical trials.

[1]  M. Wulfsohn,et al.  Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .

[2]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[3]  N. Nagelkerke,et al.  Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. , 1994, Statistics in medicine.

[4]  T. Fleming,et al.  Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.

[5]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[6]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .

[7]  W. Guerra Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .

[8]  John D. Kalbfleisch,et al.  Misspecified proportional hazard models , 1986 .

[9]  Kaizhai Shen,et al.  CD4 , 1990 .

[10]  D Y Lin,et al.  MULCOX2: a general computer program for the Cox regression analysis of multivariate failure time data. , 1993, Computer methods and programs in biomedicine.

[11]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[12]  H. White Maximum Likelihood Estimation of Misspecified Models , 1982 .

[13]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[14]  D Y Lin,et al.  MULCOX: a computer program for the Cox regression analysis of multiple failure time variables. , 1990, Computer methods and programs in biomedicine.

[15]  R. Prentice Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[16]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[17]  Nils Lid Hjort,et al.  On inference in parametric survival data models , 1992 .

[18]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[19]  E. C. Fieller The Biological Standardization of Insulin , 1940 .